Helus Pharma, Inc. (HELP)
6.11
-0.67
(-9.88%)
USD |
NASDAQ |
Nov 20, 16:00
6.18
+0.07
(+1.15%)
After-Hours: 20:00
Helus Pharma Total Liabilities (Quarterly) : 18.81M for Sept. 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 18.81M |
| June 30, 2026 | 17.57M |
| March 31, 2026 | 19.38M |
| December 31, 2025 | 16.18M |
| September 30, 2025 | 42.25M |
| June 30, 2025 | 59.05M |
| March 31, 2025 | 14.88M |
| December 31, 2024 | 9.252M |
| September 30, 2024 | 5.458M |
| June 30, 2024 | 3.519M |
| March 31, 2024 | 7.460M |
| December 31, 2023 | 6.448M |
| September 30, 2023 | 6.836M |
| June 30, 2023 | 4.534M |
| March 31, 2023 | 4.184M |
| December 31, 2022 | 3.224M |
| September 30, 2022 | 3.553M |
| Date | Value |
|---|---|
| June 30, 2022 | 4.965M |
| March 31, 2022 | 6.331M |
| December 31, 2021 | 4.802M |
| September 30, 2021 | 4.792M |
| June 30, 2021 | 5.304M |
| March 31, 2021 | 4.769M |
| December 31, 2020 | 6.577M |
| January 31, 2020 | |
| October 31, 2019 | |
| July 31, 2019 | 0.0104M |
| April 30, 2019 | 0.0114M |
| January 31, 2019 | 0.0068M |
| October 31, 2018 | 0.0127M |
| July 31, 2018 | 0.0122M |
| April 30, 2018 | 0.0006M |
| January 31, 2018 | 0.0011M |
| October 31, 2017 | 0.0124M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| NervGen Pharma Corp. | 29.09M |
| Milestone Pharmaceuticals, Inc. | 168.91M |
| Appili Therapeutics, Inc. | 15.82M |
| Clearmind Medicine, Inc. | 3.961M |
| GH Research Plc | 10.89M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 263.20M |
| Shareholders Equity (Quarterly) | 244.39M |
| Debt to Equity Ratio | 0.0039 |
| Current Ratio | 10.90 |
| Net Debt Paydown Yield | 0.89% |